Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Net Cash Flow: 2019-2024

Historic Net Cash Flow for Foghorn Therapeutics (FHTX) over the last 6 years, with Dec 2024 value amounting to -$24.9 million.

  • Foghorn Therapeutics' Net Cash Flow rose 120.63% to $16.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $33.2 million, marking a year-over-year increase of 362.89%. This contributed to the annual value of -$24.9 million for FY2024, which is 188.48% down from last year.
  • According to the latest figures from FY2024, Foghorn Therapeutics' Net Cash Flow is -$24.9 million, which was down 188.48% from $28.1 million recorded in FY2023.
  • Foghorn Therapeutics' Net Cash Flow's 5-year high stood at $77.3 million during FY2020, with a 5-year trough of -$48.9 million in FY2022.
  • In the last 3 years, Foghorn Therapeutics' Net Cash Flow had a median value of -$24.9 million in 2024 and averaged -$15.2 million.
  • As far as peak fluctuations go, Foghorn Therapeutics' Net Cash Flow spiked by 431.22% in 2020, and later plummeted by 686.82% in 2022.
  • Over the past 5 years, Foghorn Therapeutics' Net Cash Flow (Yearly) stood at $77.3 million in 2020, then crashed by 89.21% to $8.3 million in 2021, then plummeted by 686.82% to -$48.9 million in 2022, then spiked by 157.45% to $28.1 million in 2023, then slumped by 188.48% to -$24.9 million in 2024.